ClinicalTrials.gg
RecruitingNCT07019675Updated May 8, 2026

A Study of SKB518 in Patients With Lung Cancer

A Phase 2 interventional study of SKB518 and Tislelizumab in Lung Carcinoma, sponsored by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.. Recruiting at 17 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-05-08.

Sponsored by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (part of Sichuan Kelun Pharmaceutical Co.,Ltd.) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
192
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 845 studies in Lung Neoplasms with a site in China — 372 open to participants now, 419 under way, 34 of them phase 3. Lung Neoplasms · China.

Planned enrollment
167th of 586
192 · median 90
Started
2025
with 105 others
Phase 2
151 of 845
73 open now
Primary completion
2027-02
later than 239 of 418 live
Registered
665th of 845
by date

Among the 845 studies in Lung Neoplasms with a site in China, this one is the 167th largest by planned enrollment of the 586 interventional ones that give a count, is one of 106 that started in 2025, is one of 151 in phase 2, reaches primary completion later than 239 of the 418 other live ones, and was the 665th registered.

Lung Neoplasms

5,427 studies on the registry are indexed under Lung Neoplasms; 1,345 are open to participants now.

Browse Lung Neoplasms studies →

Open to participants now

372 of the 845 studies in Lung Neoplasms with a site in China are open now. Recruiting first, the newest first:

367 more — sign in →

All 372 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 995 Lung Neoplasms studies recruiting now, 684 (69%) set no upper age limit and 142 (14%) stop at 75 or younger; 45 take children under 18; 142 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 845 studies in Lung Neoplasms with a site in China, or all of them as a file.
02

Study summary

This is an open-label, multicenter, phase II study. The purpose of this study is to evaluate the safety, tolerability and preliminary anti-tumor activity of SKB518 in patients with lung cancer. Eligible subjects will receive SKB518 monotherapy, until radiographic disease progression, intolerable toxicity, discontinuation of study treatment required by the subject, or other protocol-specified treatment discontinuation criteria, whichever occurs first.

03

Conditions studied

  • Lung Carcinoma

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age between 18 and 75 years old at the time of signing the form, applicable to both males and females.
  2. Non-small cell lung cancer (NSCLC) or small cell lung cancer(SCLC) confirmed by histology or cytology.
  3. At least one measurable tumor lesion per v1.1.
  4. Performance status score of 0-1 according to the (ECOG) scale.
  5. Expected survival period ≥ 12 weeks.
  6. The function of important organs meets the requirements of the protocol.

Exclusion criteria

Exclusion Criteria:

  1. Symptomatic or uncontrolled cardiovascular disease
  2. History of noninfectious pneumonitis/interstitial lung disease (ILD) that required or has current pneumonitis/ILD;
  3. Subjects with the disease that requires systemic corticosteroid therapy (prednisolone or equivalent dose of similar drugs at a dose of >10 mg/d) or other therapy within 14 days before the first dose.
  4. (HIV) positive or history of acquired immunodeficiency syndrome (AIDS); known active syphilis infection.
  5. The Investigator considers other situations that will interfere with the evaluation of the study intervention or the safety of the subjects or the interpretation of the results of the study.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
192 participants (estimated)

Study arms

  • Experimental
    2L+ SCLC or non-Squamous NSCLC

    SKB518 monotherapy

    Drug: SKB518

  • Experimental
    2L SCLC

    SKB518+Tislelizumab or Tislelizumab monotherapy

    Drug: SKB518 · Drug: Tislelizumab

  • Experimental
    1L ES-SCLC

    SKB518+Tislelizumab+Carboplatin

    Drug: SKB518 · Drug: Tislelizumab · Drug: Carboplatin

Interventions

  • DrugSKB518

    SKB518 is administered every 3 weeks(Q3W) until radiographic disease progression, intolerable toxicity, or other protocol-specified treatment discontinuation criteria, whichever occurs first.

  • Tislelizumab is administered every 3 weeks(200 mg, Q3W) until radiographic disease progression, intolerable toxicity, or other protocol-specified treatment discontinuation criteria, whichever occurs first.

    Also known as: Tevimbra

  • Carboplatin is administered at every 3 weeks(AUC 5 mg/mL/min, Q3W) for 4 cycles

06

What researchers measure

Primary outcomes

  1. AE

    Incidence and severity of Adverse Events (AEs)

    Time frame: Up to 24 months

  2. ORR in specific arms

    Objective Response Rate (ORR) assessed by the investigators per RECIST v1.1

    Time frame: Up to 24 months

  3. PFS in specific arm

    Progression-Free Survival (PFS) assessed by the investigators per RECIST v1.1

    Time frame: Up to 24 months

Secondary outcomes

  1. PFS in specific arms

    Time from start of treatment to progression of disease (PD) or death, whichever occurs first, in patients with tumors.

    Time frame: Up to 24 months

  2. DOR in specific arms

    Time from the start of the first assessment of CR or PR in tumor patients to PD or death due to any reason.

    Time frame: Up to 24 months

  3. OS

    Time from start of treatment to death due to any reason.

    Time frame: Up to 24 months

  4. Pharmacokinetics

    Maximum and minimum drug concentrations (Cmax and Cmin) of SKB518-ADC and SKB518-TAb (antibody-drug conjugate and total antibody forms of SKB518) in Serum; Cmax and Cmin of SKB518-Free Payload in Plasma

    Time frame: Up to 24 months

  5. Immunogenicity

    Anti-Drug Antibody(ADA) Titre of SKB518

    Time frame: Up to 24 months

07

Study locations

17 of 17 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Feb 2027, 17 months after the start.

Of 77 industry-sponsored phase 2 interventional studies under Lung Neoplasms, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 61. This study's planned 17 months is below that.

Counting every sponsor, half of 363 studies reached it within 65 months; a quarter within 34 and three quarters within 102.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 5, 2025
First posted
Jun 13, 2025
StartActual
Aug 29, 2025
Primary completionEst.
Feb 20, 2027
CompletionEst.
Oct 20, 2027
Last update
May 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07019675
Responsible party
Sponsor
First posted
Jun 13, 2025
Start date
Aug 29, 2025
Primary completion
Feb 20, 2027 (estimated)
Completion
Oct 20, 2027 (estimated)
Last update
May 8, 2026

Study contacts

Xin Li
Contact
lixin@kelun.com
086-010-58202512

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anti-PTK7 Antibody-drug Conjugate SKB518

Start the discussion